"Retatrutide, which has not yet completed clinical trials, is an experimental injection developed by the US drugmaker Eli Lilly that targets three gut hormones: GLP-1, GIP and glucagon. Early studies suggest it could help patients lose up to a quarter of their body weight, leading to it being hailed online as the next Ozempic. Ozempic is not licensed in the UK as a weight-loss drug. Buying Retatrutide illegally, however, carries serious risks."
"Because the drug is still experimental, products sold online or through unofficial channels are unregulated and may not contain the correct ingredients or dosage and may not be sterilised to the correct standard. Contaminated or incorrectly dosed injectable hormones can cause infections, dangerous blood sugar crashes, pancreatitisand cardiovascular side effects. Using an unfinished clinical-trial drug outside legitimate medical settings is unsafe and potentially life-threatening."
Companies are advertising and selling experimental weight-loss drugs online while accumulating positive Trustpilot reviews, enabling high-risk operators to appear credible. Retatrutide UK displayed a 4.4 score while offering an unlicensed 20mg pen for £132. Retatrutide is an experimental injection targeting GLP-1, GIP and glucagon and has not completed clinical trials. Unregulated products sold through unofficial channels may contain incorrect ingredients or dosages and may not be sterilised, risking contamination, infection, dangerous blood sugar crashes, pancreatitis, and cardiovascular side effects. Regulators have raided illicit facilities, and academics warn that regulatory gaps draw people into unsafe markets.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]